Lightning can definitely strike the same place twice, or so it seems in biotech. The latest example is True North Therapeutics’ recent acquisition by Bioverativ for its program addressing cold agglutinin disease, a type of rare autoimmune hemolytic anemia: it

The FDA recently approved Imfinzi (durvalumab) for the treatment of bladder cancer, making it the fifth new monoclonal antibody approved this year. More than twenty antibodies have been approved by the FDA since 2015. While not quite the magic bullet envisioned

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a child, I once played the fiddler in ‘Fiddler on the Roof’. I was a horrible violinist with

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and former EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. We are excited to open the first page of Chapter 2 at Magenta

Neural networks, cloud computing, deep learning, and in silico wizardry are on the cusp of disintermediating pharmaceutical drug discovery, cutting billions of billions off the industry’s cost of new drugs and reducing the time to get new medicines approved to

This blog was written by Nessan Bermingham, CEO of Intellia Therapeutics, as part of the From The Trenches feature of LifeSciVC   Academic discoveries are oxygen for entrepreneurs. But, caveat subscriptor – be careful what you sign. Even high profile

Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these

This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. A national security threat equivalent to terrorism?  This is how

As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the

Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun.  a state in which opposing forces or influences are balanced. As I’ve noted

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. When a taxi driver finds out the name of my company, I am inevitably asked, “What does Bicycle Therapeutics

Snow sports are a passion of mine; almost any day up on a mountain is a great day. By combining this passion with a bigger purpose, I’ve recently tapped into a true vein of inspiration, integrating both my professional and